Migraines

NuPathe Inc., a privately held specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, announced positive Phase I results for NP101, a novel drug-device patch for acute migraine in clinical development.

More: continued here

Fifteen percent to 20 percent of people worldwide suffer from migraines excruciating headaches often presaged by dramatic sensations, or “auras.” By studying a rare, inherited form of migraine, researchers at Vanderbilt University Medical Center have found clues to the biological basis of the painful, debilitating disorder. In the Proceedings of the National Academy of Sciences, Alfred George Jr., M.D.

More: continued here